← All trials
NCT04411069
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 20, 2019
- Primary completion
- Sep 20, 2020
- Completion date
- Sep 20, 2020
- First posted
- Jun 2, 2020
- Last posted
- Jun 2, 2020
- Enrollment
- 768
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto do Cancer do Estado de São PauloLead sponsor
- Instituto do Cancer do Estado de São PauloStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.